Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study Twenty-one patients (escalation, n = 12; ...

Chondrosarcoma represents a heterogeneous group of primary malignant tumours arising from cartilaginous tissues. These tumours vary widely in clinical behaviour, ranging from slow-growing, locally ...

Chondrosarcoma is a malignant tumour characterised by the generation of a cartilaginous matrix by neoplastic cells. When occurring in the craniofacial region, particularly within the temporomandibular ...

Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Chondrosarcoma Market - A Global and Regional Analysis: Focus on Type, Treatment Type, and Region - Analysis and Forecast, 2025-2035" report has been ...

Mumbai: Dr Arsheed Hussain Hakeem, Senior Consultant – Surgical Oncology, Apollo Cancer Centre, Hyderabad speaking to Prabhat Prakash of ETHealthworld discussed the rarity of mesenchymal ...

Please provide your email address to receive an email when new articles are posted on . The patient is a 57-year-old, right-handed, retired postal worker. He presented with a chief complaint of ...

— Company Granted U.S. Orphan Drug Designation for IPI-926 for the Treatment of Chondrosarcoma — — Rationale for Developing IPI-926 in Chondrosarcoma to be Highlighted During a Hedgehog Pathway ...

SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for ...

(RTTNews) - Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical company, reported its third-quarter 2025 financial results and highlighted the upcoming events to watch in the coming ...